Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
7.26
CNY
-0.20
(-2.68%)
ISIN
CNE100004BN8
Return %
Stock
S&P 500
1Y
-20.04
14.20
3Y
-25.39
81.12
5Y
-50.58
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Da Jun Zhao
- Full Time Employees
- 876
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Zhangjiang Hi-Tech Park Shanghai SH China 201210
- IPO Date
- Aug 13, 2002
- Website
- fd-zj.com
- Similar Companies
- Business
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a Shanghai-based biopharmaceutical company specializing in the research, development, manufacturing, and marketing of innovative drugs and medical devices. Founded in 1996 and headquartered in Shanghai, China, the company operates across multiple R&D platforms, including genetic engineering, photodynamic therapy, nano-technology, and oral solid preparations. Its product portfolio comprises genetic engineering platform drugs such as CD30-DM1 antibody-drug conjugates (ADC) completed Phase I clinical trials for tumors; Trop2-SN38 ADC in Phase III trials for triple-negative breast cancer; Trop2-BB05, DLL3-BB05, and HER2 ADCs in Phase I clinical stages targeting various tumors. It also develops photodynamic technical platform drugs like hemoporfin for port wine stain (completed Phase IV trial) and multiple aminolevulinic acid formulations targeting cervical diseases, actinic keratosis, acne, gliomas, bladder cancer, and surgical visualization applications. Additionally, the company offers osmotic pump technology platform drugs such as controlled-release carbidopa/levodopa tablets (completed Phase II trials for early Parkinson's disease) and obeticholic acid for hepatobiliary and autoimmune diseases. Beyond pharmaceuticals, it provides medical diagnostic products, clinical laboratory analysis instruments and software, daily necessities, technology development, transfer, consulting, and promotion services. Major subsidiaries include Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd., Fernovelty (Hong Kong) Holdings Ltd., and Shanghai Tracing Bio-technology Co., Ltd. Recent significant developments at Shanghai Fudan-Zhangjiang include the dissolution of its Supervisory Committee and appointment of an employee director in late 2025. The company continues to advance its broader strategy in innovative drug commercialization, notably progressing its Trop2-SN38 ADC through Phase III trials and expanding clinical trial work on its BB05 linker-drug platform. The company has invested in scaling antibody-drug conjugate production at its Taizhou facility to support commercial readiness. It is also expanding photodynamic therapy commercialization and has made organizational governance amendments to enhance oversight in 2025. The company remains focused on strengthening industrial capabilities and accelerating innovation-driven growth through collaborations and technological enhancements in biopharmaceutical development and production. Shanghai Fudan-Zhangjiang operates in the innovative drug and medical device segments primarily serving oncology, dermatology, autoimmune, and other specialized therapeutic areas. It markets products domestically in China while actively advancing clinical programs and building production capacity to compete in global biotech markets. The company is publicly listed on the STAR Market of the Shanghai Stock Exchange under ticker 688505.SS and also on the Hong Kong Stock Exchange under 1349.HK, reflecting its A+H share structure. The comprehensive pipeline, platform technologies, recent governance reforms, and strategic investments underscore its commitment to becoming a leading integrated biopharma enterprise in China and beyond.